Diagnosis and management of adult central nervous system leukemia  

作　　者：Siyu Liu Ying Wang 

机构地区：[1]State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China [2]Tianjin Institutes of Health Science,Tianjin 301600,China

出　　处：《Blood Science》2023年第3期141-149,共9页血液科学（英文）

基　　金：supported by a Tianjin Municipal Science and Technology Commission Grant(No.20JCZDJC00120);the CAMS Innovation Fund for Medical Science(No.2020-I2M-C&T-A-019);National Key Research and Development Program of China(No.2021YFC2500304).

摘　　要：Central nervous system leukemia(CNSL)is a prominent infiltration reason for therapy failing in acute leukemia.Recurrence rates and the prognosis have alleviated with current prophylactic regimens.However,the accurate stratification of relapse risk and treatment regimens for relapsed or refractory patients remain clinical challenges yet to be solved.Recently,with hematopoietic stem cell transplantation(HSCT)and chimeric antigen receptor-T(CAR-T)cellular therapy showing encouraging effects in some CNSL patients,advances in treating CNSL have already been reported.The development of molecular targeted agents as well as antibody-based drugs will provide patients with more personalized treatment.This article summarized recent research developments about risk factors,diagnosis,prevention,and treatment in adults with CNSL.

关 键 词：Central nervous system leukemia PROPHYLAXIS Risk factors TREATMENT 

分 类 号：R733.7[医药卫生—肿瘤]